November | 2007 | GlobeImmune

GlobeImmune Announces Presentation of Results from a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection

November 06, 2007

LOUISVILLE, CO, November 6, 2007 – GlobeImmune, Inc. today announced results from the additional higher dose cohorts from the Company’s randomized, placebo-controlled Phase 1b clinical trial evaluating the safety, immunogenicity and initial efficacy of GI-5005 in patients with chronic hepatitis … Continue reading →

GlobeImmune Announces Presentation of Additional Phase 1b Hepatitis C Results at American Association for the Study of Liver Diseases 2007 Annual Meeting

November 01, 2007

LOUISVILLE, CO, November 1, 2007 – GlobeImmune, Inc. today announced that additional high dose results from the Company’s randomized, placebo-controlled Phase 1b clinical trial evaluating GI-5005 as a treatment of chronic hepatitis C infection will be the subject of a … Continue reading →